Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry

doi:10.1111/bjd.19644

. 2021 Jun;184(6):1059-1067.

doi: 10.1111/bjd.19644. Epub 2020 Nov 29.

Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry

G Dobos^{1

2

3}, A de Masson^{1

2

3}, C Ram-Wolff^{1

2

3}, M Beylot-Barry⁴, A Pham-Ledard⁴, N Ortonne⁵, S Ingen-Housz-Oro⁶, M Battistella^{2

3

7}, M d'Incan⁸, J Rouanet⁹, F Franck⁹, M D Vignon-Pennamen⁷, N Franck¹⁰, A Carlotti¹¹, S Boulinguez¹², L Lamant¹³, T Petrella¹⁴, S Dalac¹⁵, P Joly¹⁶, P Courville¹⁷, J Rivet^{4

5}, O Dereure¹⁸, F Amatore¹⁹, S Taix²⁰, F Grange²¹, A Durlach²², G Quéreux²³, N Josselin²⁴, I Moulonguet¹, L Mortier²⁵, R Dubois²⁶, E Maubec²⁷, L Laroche²⁷, L Michel^{2

3}, I Templier²⁸, S Barete²⁹, C Nardin³⁰, O Augereau³¹, B Vergier³¹, M Bagot^{1

2

3}; French Study Group on Cutaneous Lymphomas (GFELC)

Affiliations

¹ Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
² INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
³ Université de Paris, Paris, France.
⁴ Dermatology Department, Université de Bordeaux, Bordeaux, France.
⁵ Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.
⁶ Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.
⁷ Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France.
⁸ Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France.
⁹ Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France.
¹⁰ Dermatology Department, Cochin Hospital, AP-HP, Paris, France.
¹¹ Pathology Department, Cochin Hospital, AP-HP, Paris, France.
¹² Dermatology Department, Cahors Hospital, Toulouse, France.
¹³ Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France.
¹⁴ Pathology Department, Dijon Bourgogne University Hospital, Dijon, France.
¹⁵ Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France.
¹⁶ Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.
¹⁷ Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.
¹⁸ Dermatology Department, Montpellier University Hospital, Montpellier, France.
¹⁹ Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.
²⁰ Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.
²¹ Dermatology Department, Robert Debré University Hospital, Reims, France.
²² Pathology Department, Reims University Hospital, Reims, France.
²³ Dermatology Department, Nantes University Hospital, Nantes, France.
²⁴ Pathology Department, Nantes University Hospital, Nantes, France.
²⁵ Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France.
²⁶ Pathology Department, Claude Huriez University Hospital, Lille, France.
²⁷ Dermatology Department, Avicenne Hospital, AP-HP, Paris, France.
²⁸ Dermatology Department, Grenoble University Hospital, Grenoble, France.
²⁹ Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France.
³⁰ Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France.
³¹ Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France.

PMID: 33131055
DOI: 10.1111/bjd.19644

Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry

G Dobos et al. Br J Dermatol. 2021 Jun.

. 2021 Jun;184(6):1059-1067.

doi: 10.1111/bjd.19644. Epub 2020 Nov 29.

Authors

Affiliations

¹ Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
² INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
³ Université de Paris, Paris, France.
⁴ Dermatology Department, Université de Bordeaux, Bordeaux, France.
⁵ Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.
⁶ Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.
⁷ Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France.
⁸ Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France.
⁹ Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France.
¹⁰ Dermatology Department, Cochin Hospital, AP-HP, Paris, France.
¹¹ Pathology Department, Cochin Hospital, AP-HP, Paris, France.
¹² Dermatology Department, Cahors Hospital, Toulouse, France.
¹³ Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France.
¹⁴ Pathology Department, Dijon Bourgogne University Hospital, Dijon, France.
¹⁵ Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France.
¹⁶ Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.
¹⁷ Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.
¹⁸ Dermatology Department, Montpellier University Hospital, Montpellier, France.
¹⁹ Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.
²⁰ Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.
²¹ Dermatology Department, Robert Debré University Hospital, Reims, France.
²² Pathology Department, Reims University Hospital, Reims, France.
²³ Dermatology Department, Nantes University Hospital, Nantes, France.
²⁴ Pathology Department, Nantes University Hospital, Nantes, France.
²⁵ Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France.
²⁶ Pathology Department, Claude Huriez University Hospital, Lille, France.
²⁷ Dermatology Department, Avicenne Hospital, AP-HP, Paris, France.
²⁸ Dermatology Department, Grenoble University Hospital, Grenoble, France.
²⁹ Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France.
³⁰ Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France.
³¹ Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France.

PMID: 33131055
DOI: 10.1111/bjd.19644

Abstract

Background: Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time.

Objectives: The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients.

Methods: Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included.

Results: The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time.

Conclusions: Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.

PubMed Disclaimer

Comment in

Epidemiology of cutaneous lymphoma.
Vermeer M. Vermeer M. Br J Dermatol. 2021 Jun;184(6):993-994. doi: 10.1111/bjd.19829. Epub 2021 Mar 3. Br J Dermatol. 2021. PMID: 33656170 Free PMC article.

Cited by

Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center Study.
D'Onghia M, Cartocci A, Calabrese L, Maio D, Sirchio A, Erasti M, Tognetti L, Rubegni P, Bocchia M, Cencini E, Fabbri A, Cinotti E. D'Onghia M, et al. Curr Oncol. 2023 Nov 8;30(11):9813-9823. doi: 10.3390/curroncol30110712. Curr Oncol. 2023. PMID: 37999132 Free PMC article.
A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N, Martínez-Madueño F, Caballé B, Badia J, Blanes M, Bujanda DA, Calvo V, Gómez Codina J, Blanco CQ, Espinosa P, Lavernia J, Arroyo FRG, Risueño MG, Llorca C, Cumeras R, Pulla MP, Gumà J. Martínez-Banaclocha N, et al. Cancers (Basel). 2024 Mar 3;16(5):1034. doi: 10.3390/cancers16051034. Cancers (Basel). 2024. PMID: 38473391 Free PMC article.
[New treatment concepts and combination therapies for cutaneous T-cell lymphomas].
Assaf C, Dobos G. Assaf C, et al. Dermatologie (Heidelb). 2022 Oct;73(10):782-787. doi: 10.1007/s00105-022-05053-x. Epub 2022 Sep 8. Dermatologie (Heidelb). 2022. PMID: 36074144 Review. German.
Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis.
Tian Y, Li Y, Chen Y, Yuan G, Peng B, Su L, Wu J. Tian Y, et al. Front Oncol. 2025 Apr 14;15:1580550. doi: 10.3389/fonc.2025.1580550. eCollection 2025. Front Oncol. 2025. PMID: 40297814 Free PMC article.
Role of Antigenic Stimulation in Cutaneous T-Cell Lymphomas.
Gumina ME, Hooper MJ, Zhou XA, Koralov SB. Gumina ME, et al. J Invest Dermatol. 2024 Apr;144(4):755-763. doi: 10.1016/j.jid.2023.10.023. Epub 2023 Dec 26. J Invest Dermatol. 2024. PMID: 38149950 Free PMC article. Review.

See all "Cited by" articles

References

1. Abbott RA, Aldridge C, Dojcinov S, Piguet V. Incidence of primary cutaneous T-cell lymphoma in Wales. Br J Dermatol 2013; 169:1366-7.
1. Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376-9.
1. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute’s Surveillance, Epidemiology, and End Results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246-8.
1. Beylot-Barry M, Vergier B, Masquelier B et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23:1208-16.
1. Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154:1206-7.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

Translational Research Fellowship/European Society for Medical Oncology

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Abbott RA, Aldridge C, Dojcinov S, Piguet V. Incidence of primary cutaneous T-cell lymphoma in Wales. Br J Dermatol 2013; 169:1366-7.

[2] Abbott RA, Aldridge C, Dojcinov S, Piguet V. Incidence of primary cutaneous T-cell lymphoma in Wales. Br J Dermatol 2013; 169:1366-7.

[3] Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376-9.

[4] Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376-9.

[5] Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute’s Surveillance, Epidemiology, and End Results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246-8.

[6] Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute’s Surveillance, Epidemiology, and End Results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246-8.

[7] Beylot-Barry M, Vergier B, Masquelier B et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23:1208-16.

[8] Beylot-Barry M, Vergier B, Masquelier B et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23:1208-16.

[9] Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154:1206-7.

[10] Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154:1206-7.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry

Affiliations

Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical